WO2006092610A3 - Markers for melanoma - Google Patents

Markers for melanoma Download PDF

Info

Publication number
WO2006092610A3
WO2006092610A3 PCT/GB2006/000756 GB2006000756W WO2006092610A3 WO 2006092610 A3 WO2006092610 A3 WO 2006092610A3 GB 2006000756 W GB2006000756 W GB 2006000756W WO 2006092610 A3 WO2006092610 A3 WO 2006092610A3
Authority
WO
WIPO (PCT)
Prior art keywords
melanoma
methods
progression
methylation status
marker genes
Prior art date
Application number
PCT/GB2006/000756
Other languages
French (fr)
Other versions
WO2006092610A2 (en
Inventor
William Gallagher
Original Assignee
Univ Dublin
Baldock Sharon
William Gallagher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dublin, Baldock Sharon, William Gallagher filed Critical Univ Dublin
Priority to CA002600337A priority Critical patent/CA2600337A1/en
Priority to EP06709980A priority patent/EP1859049A2/en
Publication of WO2006092610A2 publication Critical patent/WO2006092610A2/en
Publication of WO2006092610A3 publication Critical patent/WO2006092610A3/en
Priority to US11/713,088 priority patent/US20090093424A1/en
Priority to EP07250877A priority patent/EP1840227A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Abstract

Methods of monitoring melanoma progression in a subject comprise, in a test sample, determining expression levels of novel marker genes. These genes are selected from, inter alia, TSPY1, CYBA and MT2A. Methods of diagnosing melanoma also include determining the methylation status of markers whose methylation status has now been shown to be linked to progression of melanoma. Microarrays, screening methods, primers and methods of treatment of melanoma are also described based around the novel marker genes.
PCT/GB2006/000756 2005-03-02 2006-03-02 Markers for melanoma WO2006092610A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002600337A CA2600337A1 (en) 2005-03-02 2006-03-02 Markers for melanoma
EP06709980A EP1859049A2 (en) 2005-03-02 2006-03-02 Markers for melanoma
US11/713,088 US20090093424A1 (en) 2006-03-02 2007-03-02 Markers for melanoma
EP07250877A EP1840227A1 (en) 2006-03-02 2007-03-02 Markers for melanoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0504302.1 2005-03-02
GB0504302A GB0504302D0 (en) 2005-03-02 2005-03-02 Markers for melanoma

Publications (2)

Publication Number Publication Date
WO2006092610A2 WO2006092610A2 (en) 2006-09-08
WO2006092610A3 true WO2006092610A3 (en) 2006-12-07

Family

ID=34430497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000756 WO2006092610A2 (en) 2005-03-02 2006-03-02 Markers for melanoma

Country Status (4)

Country Link
EP (1) EP1859049A2 (en)
CA (1) CA2600337A1 (en)
GB (1) GB0504302D0 (en)
WO (1) WO2006092610A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2390369A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the GZMB gene
US20110091377A1 (en) * 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
AU2008345036A1 (en) * 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of MINT loci and tumor-related genes as a marker for melanoma and breast cancer
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
EA019599B1 (en) * 2010-09-13 2014-04-30 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Method for diagnosis of melanoma of a human based on determination of phf 10 gene expression level, diagnostic kit
GB201204785D0 (en) 2012-03-19 2012-05-02 Queen Mary & Westfield College Method for determining prognosis of prostate cancer in a subject
EP4265740A3 (en) * 2013-03-14 2024-04-24 Castle Biosciences, Inc. Methods for predicting risk of metastasis in cutaneous melanoma
EP3798316A3 (en) * 2013-03-15 2021-06-09 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
WO2016003810A1 (en) 2014-07-02 2016-01-07 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
WO2017004153A1 (en) * 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
CN110241219B (en) * 2019-07-18 2024-04-16 北京泱深生物信息技术有限公司 Application of MYOM3 in melanoma metastasis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041815A2 (en) * 1999-12-10 2001-06-14 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
WO2004031410A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041815A2 (en) * 1999-12-10 2001-06-14 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
WO2004031410A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
APARICIO A ET AL: "Phase I trial of continuous infusion 5-aza-2'-deoxycytidine.", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 51, no. 3, March 2003 (2003-03-01), pages 231 - 239, XP002389349, ISSN: 0344-5704 *
BERGER AARON J ET AL: "Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome", CANCER RESEARCH, vol. 64, no. 23, 1 December 2004 (2004-12-01), pages 8767 - 8772, XP002389352, ISSN: 0008-5472 *
BITTNER M ET AL: "MOLECULAR CLASSIFICATION OF CUTANEOUS MALIGNANT MELANOMA BY GENE EXPRESSION PROFILING", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 406, no. 6795, 3 August 2000 (2000-08-03), pages 536 - 540, XP000990000, ISSN: 0028-0836 *
CLARK E A ET AL: "Genomic analysis of metastasis reveals an essential role for RhoC", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 406, no. 6795, 3 August 2000 (2000-08-03), pages 532 - 535, XP002333028, ISSN: 0028-0836 *
JANSSEN B L M ET AL: "TRANSCRIPTION OF THE MAGE-1 GENE AND THE METHYLATION STATUS OF ITS ETS BINDING PROMOTER ELEMENTS: A QUANTITATIVE ANALYSIS IN MELANOMA CELL LINES USING A REAL-TIME POLYMERASE CHAIN REACTION TECHNIQUE", MELANOMA RESEARCH, vol. 9, no. 3, 1999, pages 213 - 222, XP009029709 *
See also references of EP1859049A2 *
SERRANO ALFONSO ET AL: "Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-Aza-2'-deoxycytidine treatment", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 94, no. 2, 15 October 2001 (2001-10-15), pages 243 - 251, XP002348088, ISSN: 0020-7136 *
VAN DER VELDEN PIETER A ET AL: "Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development.", INTERNATIONAL JOURNAL OF CANCER, vol. 106, no. 4, 10 September 2003 (2003-09-10), pages 472 - 479, XP002389348, ISSN: 0020-7136 *
WANG ENA ET AL: "Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness", CANCER RESEARCH, vol. 62, no. 13, 1 July 2002 (2002-07-01), pages 3581 - 3586, XP002389350, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
CA2600337A1 (en) 2006-09-08
EP1859049A2 (en) 2007-11-28
GB0504302D0 (en) 2005-04-06
WO2006092610A2 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
WO2006092610A3 (en) Markers for melanoma
PL2121963T3 (en) Methods for identifying a strain isolated from a clinical sample at the species and/or subspecies level
WO2006089091A3 (en) Methods for detecting minimum residual disease
HK1154407A1 (en) Markers for prenatal diagnosis and monitoring
WO2009134944A3 (en) Methods of determining the health status of an individual
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2007047408A3 (en) Promac signature application
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2008082987A3 (en) Analyte meter protectors and methods
WO2006010150A3 (en) Housekeeping genes and methods for identifying the same
WO2007048067A3 (en) C-kit oncogene mutations in melanoma
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
WO2008144761A3 (en) Methods and compositions for identifying and treating lupus
MX2013000502A (en) Methods and kits for the diagnosis of prostate cancer.
WO2008073627A3 (en) Method of diagnosing and treating asthma
WO2013057581A3 (en) Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
WO2007002375A3 (en) Methods and compositions for analysis of microrna
EP1865067A4 (en) Method for study, determination or evaluation
WO2007071874A3 (en) Novel compounds which interact with pea-15
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2007075672A3 (en) Prognostic cancer markers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2600337

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006709980

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006709980

Country of ref document: EP